13F Holdings
中文EN

STXS Stereotaxis, Inc.

Electromedical & Electrotherapeutic Apparatus · NYSE · SEC CIK 1289340 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.8%
TTM net income YoY5.4%
TTM EPS YoY14.3%
Revenue 3-yr CAGR2.2%
Net income 3-yr CAGR—

Margins

Gross margin52.5%
Operating margin-71.9%
Net margin-70.9%
FCF margin-49.2%
EBITDA margin-69.6%

Returns

ROE-161.7%
ROA-35.0%
ROIC (approx.)-229.4%
Asset turnover0.49x

Leverage & solvency

Liabilities / assets67.7%
Debt / equity0.12x
Current ratio1.08x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.68x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue0.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$32.38M$26.92M$26.77M$28.15M$35.02M
Cost of revenue$15.31M$12.32M$11.91M$9.68M$11.79M
Gross profit$17.07M$14.59M$14.86M$18.47M$23.23M
R&D expense$9.38M$9.76M$10.27M$10.56M$10.20M
SG&A expense$17.85M$17.20M$14.05M$14.36M$13.97M
Operating income-$22.11M-$24.74M-$21.84M-$18.78M-$12.89M
Net income-$21.64M-$24.05M-$20.71M-$18.29M-$10.72M
EBITDA-$21.49M-$24.15M-$21.24M-$18.35M-$12.78M
EPS (basic)-0.25-0.30-0.27-0.26-0.16
EPS (diluted)-0.25-0.30-0.27-0.26-0.16
Weighted avg. shares (diluted)90.96M85.18M80.70M76.06M75.56M
Banking
Net interest income$467,000$694,000$1.10M$484,000-$11,000
Balance sheet
Cash & equivalents$13.42M$12.22M$19.82M$9.86M$40.14M
Short-term investments$0$0—$19.84M—
Receivables$5.85M$3.82M$3.82M$5.09M$5.41M
Inventory$9.57M$8.33M$8.43M$7.88M$4.43M
Current assets$33.85M$26.44M$33.27M$43.25M$51.39M
PP&E, net$3.02M$3.57M$3.30M$3.83M$2.63M
Goodwill$3.76M$3.76M———
Intangibles$6.43M$7.36M———
Total assets$52.25M$46.72M$41.91M$53.41M$60.98M
Current liabilities$22.36M$21.60M$13.25M$14.29M$13.26M
Total liabilities$33.53M$35.29M$19.99M$21.48M$21.56M
Shareholders' equity$13.48M$6.08M$16.34M$26.35M$33.84M
Cash flow statement
Operating cash flow-$13.69M-$8.50M-$9.14M-$8.41M-$2.95M
Capital expenditure$93,000$34,000$366,000$2.38M$1.40M
Free cash flow-$13.78M-$8.53M-$9.51M-$10.79M-$4.34M
Investing cash flow-$93,000$74,000$19.77M-$22.09M-$1.40M
Financing cash flow$14.76M$297,000$81,000$220,000$547,000
Depreciation & amortization$626,000$587,000$595,000$429,000$106,000
Stock-based compensation$9.85M$10.26M$10.62M$10.58M$9.36M
Dividends paid$0$0$0$0$0

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.